Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.99 USD
+0.23 (5.98%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 4:50 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 376 | 334 | 198 | 368 | 118 |
Receivables | 36 | 7 | 12 | 6 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 12 | 8 | 4 | 4 |
Total Current Assets | 422 | 353 | 219 | 378 | 129 |
Net Property & Equipment | 22 | 25 | 23 | 13 | 10 |
Investments & Advances | 0 | 0 | 69 | 0 | 16 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 3 | 3 | 3 | 3 |
Total Assets | 471 | 407 | 341 | 394 | 156 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 5 | 11 | 6 | 6 |
Current Portion Long-Term Debt | 4 | 13 | 9 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 53 | 28 | 11 | 9 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 21 | 17 | 9 | 15 | 20 |
Total Current Liabilities | 94 | 67 | 42 | 30 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 53 | 90 | 0 | 7 | 17 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 4 | 16 | 25 | 9 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 151 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 321 | 190 | 89 | 62 | 59 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 709 | 670 | 586 | 560 | 293 |
Retained Earnings | -559 | -453 | -333 | -228 | -196 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 150 | 217 | 253 | 332 | 98 |
Total Liabilities & Shareholder's Equity | 471 | 407 | 341 | 394 | 156 |
Total Common Equity | 150 | 217 | 253 | 332 | 98 |
Shares Outstanding | 61.00 | 57.40 | 46.20 | 38.60 | 23.00 |
Book Value Per Share | 2.45 | 3.78 | 5.47 | 8.60 | 4.25 |
Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 313 | 376 | 355 | 392 |
Receivables | NA | 31 | 36 | 17 | 10 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 10 | 10 | 9 | 10 |
Total Current Assets | NA | 355 | 422 | 381 | 412 |
Net Property & Equipment | NA | 21 | 22 | 22 | 24 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 7 | 4 | 4 | 4 |
Total Assets | NA | 403 | 471 | 432 | 465 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 9 | 6 | 4 |
Current Portion Long-Term Debt | NA | 0 | 4 | 7 | 10 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 45 | 53 | 31 | 29 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 21 | 21 | 24 | 18 |
Total Current Liabilities | NA | 80 | 94 | 74 | 67 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 46 | 53 | 78 | 80 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 151 | 143 | 137 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 305 | 321 | 319 | 310 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 716 | 709 | 703 | 696 |
Retained Earnings | NA | -618 | -559 | -590 | -541 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 98 | 150 | 112 | 155 |
Total Liabilities & Shareholder's Equity | NA | 403 | 471 | 432 | 465 |
Total Common Equity | 0 | 98 | 150 | 112 | 155 |
Shares Outstanding | 81.70 | 62.40 | 61.00 | 60.90 | 60.10 |
Book Value Per Share | 0.00 | 1.57 | 2.45 | 1.84 | 2.57 |